Yi-Jun Kim1,2, Jae-Sung Kim1, In Ah Kim3. 1. Department of Radiation Oncology, Seoul National University Bundang Hospital, 82 Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. 2. Center for Precision Medicine, Seoul National University Hospital, 101 Daehak-ro, Yeongeon-dong, Jongno-gu, Seoul, 03080, Republic of Korea. 3. Department of Radiation Oncology, Seoul National University Bundang Hospital, 82 Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. inah228@snu.ac.kr.
Abstract
PURPOSE: To evaluate the impact of molecular subtype on incidence and prognosis of brain metastasis from breast cancer. METHODS: The Surveillance, Epidemiology, and End Results (SEER) 18 registry was used to select breast cancer patients from 2010 to 2014. Molecular subtypes were classified as luminal A (hormone receptor [HR]+/human epidermal growth factor receptor 2 [HER2]-), luminal B (HR+/HER2+), HER2 (HR-/HER2+), or triple negative breast cancer (TNBC) (HR-/HER2-). The incidence and prognosis of brain metastasis was evaluated according to molecular subtype. RESULTS: Among the 206913 breast cancer patients, the HER2 subtype showed the highest incidence of brain metastasis (1.0%). HER2 and TNBC with multiple extracranial metastases (bone, liver, and lung) showed a high incidence of brain metastasis (28.0 and 30.8%, respectively). Median survival of luminal A, luminal B, HER2, and TNBC in brain metastasis was 12, 23, 10, and 6 months (p < 0.001), and in brain metastasis without visceral metastasis was 14, 34, 17, and 8 months (p < 0.001). On multivariate analysis, the order of subtype by favorable prognosis was luminal B, luminal A, HER2, and TNBC in all brain metastasis, while for brain metastasis patients without visceral metastasis, the order was luminal B, HER2, luminal A, and TNBC. CONCLUSIONS: Molecular subtype and visceral metastasis should be considered for prediction of prognosis for patients with brain metastasis. The patients with HER2 and TNBC cancer subtypes having visceral metastasis, close surveillance could contribute to early detection of brain metastasis and may putatively lead to improved quality of life and survival.
PURPOSE: To evaluate the impact of molecular subtype on incidence and prognosis of brain metastasis from breast cancer. METHODS: The Surveillance, Epidemiology, and End Results (SEER) 18 registry was used to select breast cancerpatients from 2010 to 2014. Molecular subtypes were classified as luminal A (hormone receptor [HR]+/human epidermal growth factor receptor 2 [HER2]-), luminal B (HR+/HER2+), HER2 (HR-/HER2+), or triple negative breast cancer (TNBC) (HR-/HER2-). The incidence and prognosis of brain metastasis was evaluated according to molecular subtype. RESULTS: Among the 206913 breast cancerpatients, the HER2 subtype showed the highest incidence of brain metastasis (1.0%). HER2 and TNBC with multiple extracranial metastases (bone, liver, and lung) showed a high incidence of brain metastasis (28.0 and 30.8%, respectively). Median survival of luminal A, luminal B, HER2, and TNBC in brain metastasis was 12, 23, 10, and 6 months (p < 0.001), and in brain metastasis without visceral metastasis was 14, 34, 17, and 8 months (p < 0.001). On multivariate analysis, the order of subtype by favorable prognosis was luminal B, luminal A, HER2, and TNBC in all brain metastasis, while for brain metastasispatients without visceral metastasis, the order was luminal B, HER2, luminal A, and TNBC. CONCLUSIONS: Molecular subtype and visceral metastasis should be considered for prediction of prognosis for patients with brain metastasis. The patients with HER2 and TNBC cancer subtypes having visceral metastasis, close surveillance could contribute to early detection of brain metastasis and may putatively lead to improved quality of life and survival.
Entities:
Keywords:
Brain metastasis; Breast cancer; Incidence; Molecular subtype; Prognosis
Authors: Eunpi Cho; Lena Rubinstein; Philip Stevenson; Ted Gooley; Mark Philips; Lia M Halasz; Michael F Gensheimer; Hannah M Linden; Jason K Rockhill; Vijayakrishna K Gadi Journal: Breast Cancer Res Treat Date: 2015-02-01 Impact factor: 4.872
Authors: David G Hicks; Sarah M Short; Nichole L Prescott; Shannon M Tarr; Kara A Coleman; Brian J Yoder; Joseph P Crowe; Toni K Choueiri; Andrea E Dawson; G Thomas Budd; Raymond R Tubbs; Graham Casey; Robert J Weil Journal: Am J Surg Pathol Date: 2006-09 Impact factor: 6.394
Authors: Catharina Bartmann; Joachim Diessner; Maria Blettner; Sebastian Häusler; Wolfgang Janni; Rolf Kreienberg; Mathias Krockenberger; Lukas Schwentner; Roland Stein; Tanja Stüber; Achim Wöckel; Manfred Wischnewsky Journal: Breast Date: 2016-11-02 Impact factor: 4.380
Authors: Olivier Graesslin; Bassam S Abdulkarim; Charles Coutant; Florence Huguet; Zsolt Gabos; Limin Hsu; Olivier Marpeau; Serge Uzan; Lajos Pusztai; Eric A Strom; Gabriel N Hortobagyi; Roman Rouzier; Nuhad K Ibrahim Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: C Dilara Savci-Heijink; Hans Halfwerk; Gerrit K J Hooijer; Hugo M Horlings; Jelle Wesseling; Marc J van de Vijver Journal: Breast Cancer Res Treat Date: 2015-03-29 Impact factor: 4.872
Authors: André Hennigs; Fabian Riedel; Adam Gondos; Peter Sinn; Peter Schirmacher; Frederik Marmé; Dirk Jäger; Hans-Ulrich Kauczor; Anne Stieber; Katja Lindel; Jürgen Debus; Michael Golatta; Florian Schütz; Christof Sohn; Jörg Heil; Andreas Schneeweiss Journal: BMC Cancer Date: 2016-09-15 Impact factor: 4.430
Authors: Diogo Mendes; Carlos Alves; Noémia Afonso; Fátima Cardoso; José Luís Passos-Coelho; Luís Costa; Sofia Andrade; Francisco Batel-Marques Journal: Breast Cancer Res Date: 2015-11-17 Impact factor: 6.466
Authors: Priscilla K Stumpf; Diana M Cittelly; Tyler P Robin; Julie A Carlson; Kelly A Stuhr; Maria Jose Contreras-Zarate; Steven Lai; D Ryan Ormond; Chad G Rusthoven; Laurie E Gaspar; Rachel Rabinovitch; Brian D Kavanagh; Arthur Liu; Jennifer R Diamond; Peter Kabos; Christine M Fisher Journal: Clin Cancer Res Date: 2019-04-02 Impact factor: 12.531
Authors: Daisuke Yamashita; Mutsuko Minata; Ahmed N Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D Bernstock; Shuko Harada; Richard A Cerione; Bakhos A Tannous; Concettina La Motta; Ichiro Nakano Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: Matthew N Mills; Chetna Thawani; Nicholas B Figura; Daniel E Oliver; Aixa E Soyano; Arnold Etame; Timothy J Robinson; James K Liu; Michael A Vogelbaum; Peter A Forsyth; Brian J Czerniecki; Hatem H Soliman; Hyo S Han; Hsiang-Hsuan Michael Yu; Kamran A Ahmed Journal: J Neurooncol Date: 2021-03-19 Impact factor: 4.130
Authors: Jennifer A Geisler; Jonathan M Spehar; Sarah A Steck; Anna Bratasz; Reena Shakya; Kimerly Powell; Gina M Sizemore Journal: J Vis Exp Date: 2020-06-07 Impact factor: 1.355
Authors: Markus Kuksis; Yizhuo Gao; William Tran; Christianne Hoey; Alex Kiss; Adam S Komorowski; Aman J Dhaliwal; Arjun Sahgal; Sunit Das; Kelvin K Chan; Katarzyna J Jerzak Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300